|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1989-12-18
|
|
pubmed:abstractText |
Granulocyte colony stimulating factor (G-CSF) was given to 17 patients with advanced breast and ovarian cancer in order to increase the intensity and effectiveness of chemotherapy. Treatment with doxorubicin, at doses of 75 mg m-2 (n = 4 patients), 100 mg m-2 (n = 5), 125 mg m-2 (n = 6) and 150 mg m-2 (n = 2), was followed by infusion of G-CSF for 11 days. G-CSF administration resulted in a return of the absolute neutrophil count to normal or above normal levels within 12-14 days at all dose levels of doxorubicin used and allowed the administration of up to three cycles of high dose chemotherapy at 14 day intervals. An absolute neutrophil count greater than 2.5 x 10(9)l-1 was not reached until day 19-21 after 75 mg m-2 of doxorubicin given without G-CSF. At doses of doxorubicin of 125 mg m-2 and 150 mg m-2 all tumours regressed rapidly, although there was marked epithelial toxicity. The overall response rate in patients with advanced breast cancer was 80% with a median time to progression of 6 months. Two months after doxorubicin-G-CSF therapy there was a pronounced improvement of symptoms compared with before treatment. Thus the effectiveness of chemotherapy may be enhanced and treatment duration shortened by the use of G-CSF infusions. Further studies of this promising approach are warranted.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/2478178-2412630,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2478178-2829955,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2478178-3047340,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2478178-3063320,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2478178-3279894,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2478178-3311358,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2478178-3318902,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2478178-346216,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2478178-3525764,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2478178-3806165,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2478178-6082300,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2478178-6357805,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2478178-688281,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2478178-6999898,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2478178-7060037,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2478178-856236
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
60
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
121-5
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:2478178-Adult,
pubmed-meshheading:2478178-Aged,
pubmed-meshheading:2478178-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:2478178-Breast Neoplasms,
pubmed-meshheading:2478178-Colony-Stimulating Factors,
pubmed-meshheading:2478178-Doxorubicin,
pubmed-meshheading:2478178-Drug Synergism,
pubmed-meshheading:2478178-Female,
pubmed-meshheading:2478178-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:2478178-Granulocytes,
pubmed-meshheading:2478178-Humans,
pubmed-meshheading:2478178-Leukocyte Count,
pubmed-meshheading:2478178-Middle Aged,
pubmed-meshheading:2478178-Neutrophils,
pubmed-meshheading:2478178-Ovarian Neoplasms
|
|
pubmed:year |
1989
|
|
pubmed:articleTitle |
The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer.
|
|
pubmed:affiliation |
Cancer Research Campaign Department of Medical Oncology, Paterson Institute for Cancer Research, Christie Hospital and Holt Radium Institute, Manchester, UK.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
